Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 309

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 19
Chunk 309
---
 required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

/s/ Deloitte & Associés

Paris la Défense, France

April 3, 2024 (April 30, 2025 as to the effects of the offset of deferred taxes presentation described in Note 16)

Deloitte & Associés have served as the Company’s auditor since 2014.

F-5

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

(amounts in thousands of euro)

                                                       Year Ended December 31,                                                                                    
                                                                          Note      2022                            2023                    2024                  
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  ASSETS                                                                                                                                                          
  Non-current assets                                                                                                                                              
  Intangible assets                                                          6                     1,556             416                       —                  
  Property and equipment                                                     7                     8,542                        6,322                      5,133  
  Non-current financial assets                                               4                    35,119                        9,796                     10,281  
  Other non-current assets                                                           149                              87                     575                  
  Trade receivables and others - non-current                                 5                    14,099                       10,554                      9,328  
  Total non-current assets                                                                        59,465                       27,175                     25,317  
  Current assets                                                                                                                                                  
  Cash and cash equivalents                                                  4                    84,225                       70,605                     66,396  
  Short-term investments                                                     4                    17,260                       21,851                     14,374  
  Trade receivables and others - current                                     5                    38,346                       55,557                      4,972  
  Total current assets                                                                           139,831                      148,013                     85